Jan 27, 2021

Smart healthcare among Bloomberg's top 100 investment ideas

smart healthcare
cancer treatment
Leila Hawkins
3 min
Smart healthcare among Bloomberg's top 100 investment ideas
Bloomberg’s report on the top 100 investments ideas for 2021 includes smart healthcare initiatives and innovative new treatments...

Bloomberg Intelligence (BI) has released its first ever “100 Investment Ideas to Watch for 2021” report, with analysis on the global public companies, credits and market strategies that will significantly develop this year. 

The list is an expansion from BI’s traditional 50 companies to watch that are featured every year in the Bloomberg Businessweek The Year Ahead issue. 

The report highlights companies across an array of industries that are set to grow as the global economy recovers from the Covid-19 pandemic. Within healthcare, themes include smart healthcare, new products, and the post-pandemic recovery. 

Technology transformed healthcare around the globe in 2020, and companies will increase investment in new products and distribution channels this year. The report highlights that digitization is creating new opportunities in pharmacies, health monitoring and insurance, among other areas. Companies to watch include: 

  • Alibaba Health. The Hong Kong-based company focuses primarily on providing internet solutions for the medical and pharmaceutical industry. In 2020 stocks rose by 136% as the pandemic fuelled healthcare spending. It is positioned to dominate online drug sales in China, while the country’s push to separate drug dispensaries from hospitals and improve reimbursements will unlock major potential in a market projected to grow by 30% each year until 2024. 
  • Teladoc. US-based, multinational telemedicine and virtual healthcare company Teladoc has benefited from the widespread adoption of telehealth, and is set to capitalise on these gains. Its $18.5 billion purchase of health-monitoring company Livongo gives it a way to tackle chronic care, for instance for diabetes and hypertension.
  • ZhongAn Insurance. China’s first online-only insurance company offers low cost medical policies that are meeting the increasing demand for healthcare coverage in the country. Its deal with Alibaba to sell its policies put the firm on track for an underwriting profit for the first time since it was founded in 2013. 

Bloomberg’s analysts found the following companies set to launch innovative new products or updates in 2021: 

  • Intercept Pharmaceuticals. Although the FDA recently rejected their treatment for a type of liver inflammation called nonalcoholic steatohepatitis, if approved after resubmission in 2021 it would leave the company well-positioned to carve out a substantial lead in this area, which has high unmet medical need.
  • Illumina. Illumina develops tools for genetic analysis. Its acquisition of cancer diagnostics company Grail and a successful 2021 launch of its Galleri test could make Illumina the clear leader in a multibillion-dollar cancer-screening market, with liquid biopsies or minimally invasive blood tests. 
  • Hutchison China MediTech. This biopharmaceutical company has a growing portfolio of cancer treatments. This has recently included colorectal cancer drug Elunate, along with drugs for neuroendocrine tumors and lung cancer which are set to launch this year. 
  • Seagen. This biotech company focuses on cancer care through antibody-based treatments. There is growing acceptance of this relatively new type of drug, and in 2020 they gained approval for breast and bladder cancer products. This year they are set to receive approval for cervical cancer treatment. 

Additionally Tenet Healthcare Corp, a large US healthcare provider, is mentioned as a firm set to increase profits once the pandemic is under control, thanks to acquiring a portfolio of surgery centres in 2020. 

Commenting on the report, Bloomberg Intelligence’s Chief Equity Strategist Gina Martin Adams said: “As markets look to the fits and starts of the emerging economic recovery and additional stimulus from U.S. policymakers to drive the overall trend, the BI100 offers analysis focused on data and deep industry expertise to identify enduring opportunities for the year ahead. 

“This report serves as a guide to actionable insights in a pivotal year that will change how and where people work, how individuals and companies will be taxed, and which industries will thrive in the post-pandemic economy.”

Share article

Jun 15, 2021

 NHS trials test that predicts sepsis 3 days in advance 

2 min
Queen Alexandra Hospital is trialling a new sepsis test by Presymptom Health that uses machine learning to detect the onset of the disease

A new test that can predict sepsis before the patient develops symptoms is being trialled at a National Health Service (NHS) hospital in the south of England. 

Clinicians at Portsmouth’s Queen Alexandra Hospital are leading medical trials of the blood test, which they hope will help them save thousands of lives a year. 

The test is being developed by government spin-out company Presymptom Health, but the research began over 10 years ago at the Defence Science and Technology Laboratory (Dstl). This included a study of 4,385 patients and more than 70,000 samples, the largest study of its kind at the time. 

From the samples taken, a clinical biobank and database were generated and then mined using machine learning to identify biomarker signatures that could predict the onset of sepsis. The researchers found they were able to provide an early warning of sepsis up to three days ahead of illness with an accuracy of up to 90%.

Unlike most other tests, Presymptom Health identifies the patient’s response to the disease as opposed to detecting the pathogen. This is an important differentiator, as sepsis occurs as a result of the patient's immune system’s overreaction to an infection or injury, which can then cause life-threatening organ dysfunction. 

Worldwide, an estimated 49 million people a year contract sepsis, while in the UK almost two million patients admitted to hospital each year are thought to be at risk of developing the condition. If Presymptom's test is effective, it could save billions of pounds globally and improve clinical outcomes for millions of sepsis patients.

The initial trials at Queen Alexandra Hospital will last 12 months, with two other sites planned to go live this summer. Up to 600 patients admitted to hospital with respiratory tract infections will be given the option to participate in the trial. The data collected will be independently assessed and used to refine and validate the test, which could be available for broader NHS use within two years. 

If successful, this test could also identify sepsis arising from other infections before symptoms appear, which could potentially include future waves of COVID-19 and other pandemics.

Dr Roman Lukaszewski, the lead Dstl scientist behind the innovation, said: “It is incredible to see this test, which we had originally begun to develop to help service personnel survive injury and infection on the front line, is now being used for the wider UK population, including those fighting COVID-19.”

Share article